Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Epizyme stock | 11.85

Own Epizyme stock in just a few minutes.

Posted

Fact checked

Epizyme, Inc is a biotechnology business based in the US. Epizyme shares (EPZM) are listed on the NASDAQ and all prices are listed in US Dollars. Epizyme employs 203 staff and has a trailing 12-month revenue of around USD$13.8 million.

How to buy shares in Epizyme

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Epizyme. Find the stock by name or ticker symbol: EPZM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Epizyme reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$11.85, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Epizyme, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Epizyme. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Epizyme's share price?

Since the stock market crash in March caused by coronavirus, Epizyme's share price has had significant negative movement.

Its last market close was USD$11.85, which is 52.37% down on its pre-crash value of USD$24.88 and 18.99% down on the lowest point reached during the March crash when the shares fell as low as USD$14.1.

If you had bought USD$1,000 worth of Epizyme shares at the start of February 2020, those shares would have been worth USD$721.82 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$553.99.

Epizyme share price

Use our graph to track the performance of EPZM stocks over time.

Epizyme shares at a glance

Information last updated 2020-10-20.
Latest market close USD$11.85
52-week range USD$10.51 - USD$27.82
50-day moving average USD$12.5129
200-day moving average USD$15.1536
Wall St. target price USD$28.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.862

Buy Epizyme shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Epizyme stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Epizyme price performance over time

Historical closes compared with the close of $11.85 from 2020-11-16

1 week (2020-11-17) 2.95%
1 month (2020-10-23) -11.04%
3 months (2020-08-24) -7.49%
6 months (2020-05-22) -36.22%
1 year (2019-11-22) -27.83%
2 years (2018-11-23) 59.49%
3 years (2017-11-24) -0.42%
5 years (2015-11-24) -23.20%

Epizyme financials

Revenue TTM USD$13.8 million
Gross profit TTM USD$-108,839,000
Return on assets TTM -31.98%
Return on equity TTM -65.22%
Profit margin 0%
Book value $2.535
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

Shorting Epizyme shares

There are currently 10.4 million Epizyme shares held short by investors – that's known as Epizyme's "short interest". This figure is 12% up from 9.3 million last month.

There are a few different ways that this level of interest in shorting Epizyme shares can be evaluated.

Epizyme's "short interest ratio" (SIR)

Epizyme's "short interest ratio" (SIR) is the quantity of Epizyme shares currently shorted divided by the average quantity of Epizyme shares traded daily (recently around 937374.8870822). Epizyme's SIR currently stands at 11.07. In other words for every 100,000 Epizyme shares traded daily on the market, roughly 11070 shares are currently held short.

However Epizyme's short interest can also be evaluated against the total number of Epizyme shares, or, against the total number of tradable Epizyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Epizyme's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Epizyme shares in existence, roughly 100 shares are currently held short) or 0.1382% of the tradable shares (for every 100,000 tradable Epizyme shares, roughly 138 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Epizyme.

Find out more about how you can short Epizyme stock.

Epizyme share dividends

We're not expecting Epizyme to pay a dividend over the next 12 months.

Epizyme share price volatility

Over the last 12 months, Epizyme's shares have ranged in value from as little as $10.51 up to $27.82. A popular way to gauge a stock's volatility is its "beta".

EPZM.US volatility(beta: 1.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Epizyme's is 1.8014. This would suggest that Epizyme's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Epizyme overview

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site